大流行四年后,管理COVID-19急性凝血病患者的经验与启示
本文回顾COVID-19相关凝血病从早期高发微血管和大血管血栓事件到因自然感染和疫苗接种获得免疫及新变异株出现后发病率与表现的变化,指出基于早期经验的诊断标准和管理策略需重新评估,并探讨如何为新兴感染病原体的止血后果做好准备。
要点
- COVID-19相关凝血病的发病率和表现随免疫背景和新变异株出现而变化。
- 基于早期经验的诊断标准和管理策略需重新评估。
- 冬季与其他感染合并时凝血病可能叠加,需为新兴病原体止血后果做准备。
核心结论
- COVID-19相关凝血病的发病率和表现已因自然感染和疫苗接种获得的免疫及新变异株出现而改变,基于早期经验的诊断标准和管理策略需重新评估。
研究设计与样本
- 本文为评论性文章,回顾大流行期间关于COVID-19相关凝血病的经验与启示。
主要发现
- 大流行初期,凝血病伴随微血管和大血管血栓事件是急性COVID-19患者的常见特征。
- 过去4年,由于自然感染和疫苗接种获得的免疫及新SARS-CoV-2变异株的出现,COVID-19相关凝血病的发病率和表现已发生变化。
- 许多其他感染性疾病状态也伴随止血功能障碍,COVID-19相关凝血病可能与其他感染病因叠加,尤其在冬季月份。
临床怎么用
- 原文未据此给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Coagulopathy alongside micro- and macrovascular thrombotic events were frequent characteristics of patients presenting with acute COVID-19 during the initial stages of the pandemic. However, over the past 4 years, the incidence and manifestations of COVID-19-associated coagulopathy have changed due to immunity from natural infection and vaccination and the appearance of new SARS-CoV-2 variants. Diagnostic criteria and management strategies based on early experience and studies for COVID-19-associated coagulopathy thus require reevaluation. As many other infectious disease states are also associated with hemostatic dysfunction, the coagulopathy associated with COVID-19 may be compounded, especially throughout the winter months, in patients with diverse etiologies of COVID-19 and other infections. This commentary examines what we have learned about COVID-19-associated coagulopathy throughout the pandemic and how we might best prepare to mitigate the hemostatic consequences of emerging infection agents.
引用
- Iba T, Levy JH, Maier CL, et al. Four years into the pandemic, managing COVID-19 patients with acute coagulopathy: what have we learned? J Thromb Haemost. 2024. PMID: 38428590. doi:10.1016/j.jtha.2024.02.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。